# RECEIVED CENTRAL FAX CENTER

JAN 2 5 2008

Intarcia Dkt No. ALE 054.11 USSN: 09/976,228 PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.

Signature

Date of Transmittal

In Re Application of: KLEINER, Lothar, et al.	Confirmation No.: 9517
Serial No.: 09/976,228	Art Unit: 1616
Filing Date: 12 October 2001	Examiner: Brown, C.A.

### REVOCATION AND SUBSTITUTE POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The above-identified patent application is a continuation of U.S. Patent Application No. 09/213,213, filed 12-17-1998, now U.S. Patent No. 6,375,978, which claims priority from U.S. Provisional Patent Application No. 60/068,377, filed 12-22-1997, now expired.

The undersigned has reviewed all the documents in the chain of title pursuant to 37 C.F.R. §3.73, and to the best of the undersigned's knowledge, Intarcia Therapeutics, Inc., is the assignee of the entire right, title, and interest in this application, specifically: the assignment recorded on 3/5/1998 at Rcel/Frame 9023/0239, and the assignment recorded on 12/13/2007 at Reel/Frame 020252/0143.

Intarcia Therapeutics, Inc., hereby revokes all powers of attorney previously given and hereby appoints the following attorney and agent to prosecute this application and to make alterations and amendments therein. Each of the following attorney and agent has full power of substitution and revocation:

Barbara G. McClung (Registration No. 33,113) Gary R. Fabian (Registration No. 33,875)

## RECEIVED CENTRAL FAX CENTER

Intarcia Dkt No. ALE 054.11 USSN: 09/976,228

JAN 25 2008

PATENT

Please direct all future correspondences in connection with this application to:

Customer Number: 000074866

Barbara G. McClung, Esq. Vice President, General Counsel and Corporate Secretary Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608

Phone: (510) 652-2600 Fax: (510) 652-2657

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number ALE 054.11) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

: 1/17/08

By: ////

arbara G. McClung, Esq.

Vice President, General Counsel and

Corporate Secretary
Intarcia Therapeutics, Inc.
Registration No. 33,113

Respectfully submitted,

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608

Phone: (510) 652-2600 Fax: (510) 652-2657

### FARSIGHT/HIGH TECHNI RECEIVED CENTRAL FAX CENTER

JAN 2 5 2008 Intarcia Dkt No. ALE 054.11

USSN: 09/976,228 PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated. R. Falran 25 January 2008 Signature Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: KLEINER, Lothar, et al.	Confirmation No.: 9517
Serial No.: 09/976,228	Art Unit: 1616
Filing Date: 12 October 2001	Examiner: Brown, C.A.
Title: RATE CONTROLLING MEMBRANES I	FOR CONTROLLED DRUG DELIVERY DEVICES

#### CHANGE OF BIBLIOGRAPHIC DATA: ATTORNEY DOCKET NUMBER AND CORRESPONDENCE ADDRESS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please change the bibliographic data for the above-referenced application to the following:

Attorney Docket No.: ALE 054.11

Correspondence Address: Customer No. 000074866

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number ALE 054.11) any fcos under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 25 January 2008

Jany R. Falsan

Gary R. Fabian, Ph.D. Registration No. 33,875 Agent for Applicants

Intarcia Therapeutics, Inc. 2000 Powell Street Suite 1640 Emeryville, CA 94608

Phone: (510) 652-2600 / Fax: (510) 652-2657